MRC Pandemic Preparedness Funding - The Francis Crick Institute

Key facts

Disease
COVID-19
Start & end year
2021
2021
Known Financial Commitments (USD)
$1,688,850
Funder
UK Research and Innovation (UKRI)
Principal Investigator
N/A
Research Location
United Kingdom
Lead Research Institution
The Francis Crick Institute
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

This funding will enable the Institute to address two major aims: i) understanding the coronavirus pathogen, including viral assembly, host factors and exploitation of structural components for the development of therapeutic targets; ii) understanding the features of host response to infection that shape protective or pathological responses and defining correlates of immunity and immune pathology.

41 Publications linked via Europe PMC

Last Updated:6 days ago

View all publications at Europe PMC

WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.

SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies.

Three-dose vaccination elicits neutralising antibodies against omicron.

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.

Authors
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Cerrone M, Schmitt AM, Joharatnam-Hogan N, Shum B, Tippu Z, Rzeniewicz K, Boos LA, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Sarker S, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Bazin J, Gordon W, Barber T, Emslie-Henry A, Xie W, Gerard CL, Deng D, Wall EC, Agua-Doce A, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Dowdie L, Ash N, Gronthoud F, Shea RL, Gardner G, Murray D, Kinnaird F, Cui W, Pascual J, Rodney S, Mencel J, Curtis O, Stephenson C, Robinson A, Oza B, Farag S, Leslie I, Rogiers A, Iyengar S, Ethell M, Messiou C, Cunningham D, Chau I, Starling N, Turner N, Welsh L, van As N, Jones RL, Droney J, Banerjee S, Tatham KC, O'Brien M, Harrington K, Bhide S, Okines A, Reid A, Young K, Furness AJS, Pickering L, Swanton C, Crick COVID-19 Consortium, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Kumar S, Yousaf N, Jhanji S, Nicholson E, Howell M, Walker S, Wilkinson RJ, Larkin J, Turajlic S, CAPTURE Consortium.
Publish Year
2021
Journal
Nature cancer
DOI
10.1038/s43018-021-00274-w

View at Europe PMC

MRC Pandemic Preparedness Funding - The Francis Crick Institute

Key facts

Abstract

41 Publications linked via Europe PMC

WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed.

SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies.

Three-dose vaccination elicits neutralising antibodies against omicron.

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.

Evolution of the SARS-CoV-2 spike protein in the human host.

Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort.

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase.

An improved method for the incorporation of fluoromethyl ketones into solid phase peptide synthesis techniques.

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease.